Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 ...
Why olezarsen data and conference appearances matter for Ionis Pharmaceuticals stock Ionis Pharmaceuticals (IONS) is back in focus after fresh updates on its late stage pipeline, including new Phase 3 ...
The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...
The findings supporting bepiroversen were deemed a “historic moment” by physicians and validate a drug that has “clear ...
CARLSBAD, Calif.-- (BUSINESS WIRE)--May 28, 2026-- ...
GSK (GSK) announced on Thursday that its antisense oligonucleotide bepirovirsen, developed with Ionis Pharma (IONS), reached ...
An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...
IONS stock advanced after partner GSK released positive Phase 3 data for bepirovirsen, showing 19% functional cure rates ...
Key Points Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better. Ionis has a packed 2026-style ...
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Ionis Pharmaceuticals (IONS) trades at $72.70 with Barclays raising its price target to $106, citing a projected $4 billion peak sales opportunity for olezarsen in severe hypertriglyceridemia with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results